Previous 10 | Next 10 |
Journal of Clinical Psychiatry Publishes Data from Alkermes' ENLIGHTEN-Early Study of LYBALVI® (olanzapine and samidorphan) in Young Adults Early in Their Illness PR Newswire DUBLIN , March 23, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today annou...
Alkermes to Participate in the Stifel 2023 CNS Days PR Newswire DUBLIN , March 15, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat as part of the Stifel 2023 CNS Days on Wednesday, March 2...
Alkermes Plc ( NASDAQ: ALKS ) rose 2.6% amid speculation that activist Sarissa Capital Management could target the company in a possible proxy battle after a win on Tuesday against Amarin ( AMRN ). Sarissa, which is one of Alkermes ( ALKS ) biggest holders with 14 million ...
The following slide deck was published by Alkermes plc in conjunction with their 2022 Q4 earnings call. For further details see: Alkermes plc 2022 Q4 - Results - Earnings Call Presentation
Alkermes plc (ALKS) Q4 2022 Earnings Conference Call February 16, 2023 8:00 A.M. ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations and Corporate Affairs Todd Nichols - Chief Commercial Officer Iain Brown - Chief Financial Officer R...
Alkermes press release ( NASDAQ: ALKS ): Q4 Non-GAAP EPS of $0.14 beats by $0.09 . Revenue of $304.67M (-6.1% Y/Y) beats by $14.87M . For FY2023, the company expects adjusted EPS of $0.12 vs. consensus of $0.36. For further details see: Alkermes Non-GAAP EPS ...
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023 PR Newswire — Revenues of $1.11 Billion in 2022, GAAP Loss per Share of $0.97 and Diluted Non-GAAP Earnings per Share of $0....
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 16, 2023 PR Newswire DUBLIN , Feb. 9, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. GMT ) on ...
Alkermes Awarded Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma PR Newswire — Designation Marks Entry Point into MHRA's Innovative Licensing and Access Pathway (ILAP) Program in the UK — DUBLI...
The following slide deck was published by Alkermes plc in conjunction with this event. For further details see: Alkermes (ALKS) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow
News, Short Squeeze, Breakout and More Instantly...
Alkermes to Report Second Quarter Financial Results on July 24, 2024 PR Newswire DUBLIN , July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. BST ) on Wednesday, ...
2024-06-29 16:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-19 17:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...